Literature DB >> 9105682

Sequence, splice site and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7.

D A Nielsen1, G L Jenkins, K M Stefanisko, K K Jefferson, D Goldman.   

Abstract

A human tryptophan hydroxylase intron seven polymorphism previously associated with low CSF 5-HIAA and suicidal behavior was sequenced and characterized for its potential role in TPH pre-mRNA splicing. Two polymorphic sites were identified: A218C and A779C. The 779A allelic frequency in various populations ranged from 0.43 to 0.61 and was in strong linkage disequilibrium with the A218C site. A218C provides a site for restriction fragment length polymorphism analysis. TPH mRNA was reverse-transcribed and sequenced. No aberrant splice products from the 779A or 779G TPH genes were detected nor were any other polymorphic nucleotides found.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9105682     DOI: 10.1016/s0169-328x(96)00304-x

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  22 in total

1.  Candidate gene polymorphisms among North Indians and their association with schizophrenia in a case-control study.

Authors:  Prachi Semwal; Suman Prasad; Panchami G Varma; A M Bhagwat; S N Deshpande; B K Thelma
Journal:  J Genet       Date:  2002-08       Impact factor: 1.166

Review 2.  Further clarification of the contribution of the tryptophan hydroxylase (TPH) gene to suicidal behavior using systematic allelic and genotypic meta-analyses.

Authors:  Dawei Li; Lin He
Journal:  Hum Genet       Date:  2006-02-01       Impact factor: 4.132

Review 3.  Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment.

Authors:  Vadim Yuferov; Orna Levran; Dmitri Proudnikov; David A Nielsen; Mary Jeanne Kreek
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

4.  Interaction between tryptophan hydroxylase I polymorphisms and childhood abuse is associated with increased risk for borderline personality disorder in adulthood.

Authors:  Scott T Wilson; Barbara Stanley; David A Brent; Maria A Oquendo; Yung-yu Huang; Fatemeh Haghighi; Colin A Hodgkinson; J John Mann
Journal:  Psychiatr Genet       Date:  2012-02       Impact factor: 2.458

5.  Interaction between TPH1 and GNB3 genotypes and electroconvulsive therapy in major depression.

Authors:  S Anttila; K Huuhka; M Huuhka; R Rontu; K M Mattila; E Leinonen; T Lehtimäki
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

6.  Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers.

Authors:  E G Jönsson; D Goldman; G Spurlock; J P Gustavsson; D A Nielsen; M Linnoila; M J Owen; G C Sedvall
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 7.  Blood-based biomarkers predicting response to antidepressants.

Authors:  Yasmin Busch; Andreas Menke
Journal:  J Neural Transm (Vienna)       Date:  2018-01-27       Impact factor: 3.575

Review 8.  From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes.

Authors:  Alessandro Serretti; Paola Artioli
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

9.  Clinical and genetic risk factors for suicide under the influence of alcohol in a Polish sample.

Authors:  Sylwia Fudalej; Mark Ilgen; Marcin Fudalej; Marcin Wojnar; Halina Matsumoto; Kristen Lawton Barry; Rafal Ploski; Frederic C Blow
Journal:  Alcohol Alcohol       Date:  2009 Sep-Oct       Impact factor: 2.826

10.  The tryptophan hydroxylase-1 A218C polymorphism is associated with diagnosis, but not suicidal behavior, in borderline personality disorder.

Authors:  Scott T Wilson; Barbara Stanley; David A Brent; Maria A Oquendo; Yung-yu Huang; J John Mann
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-03-05       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.